Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patent Applications: Apr 10, 2008

Premium
Title: Method and Devices for Analyzing Small RNA Molecules
 
Number: 20080081330
 
Filed: Sept. 28, 2006
 
Inventor: Avak Kahvejian, Helicos Biosciences
 
The invention “provides methods and devices for detecting, enumerating, and/or identifying small RNA molecules using single-molecule sequencing techniques,” the patent application’s abstract states.
 
Specifically, the method involves “modifying a small RNA molecule contained in the biological sample with an adaptor; attaching the modified small RNA molecule to a surface wherein individual small RNA molecules are positioned on the surface such that individual small RNA molecules are individually optically resolvable; and analyzing the attached modified small RNA molecule, wherein at least one nucleotide is identified in at least one attached modified small RNA molecule, thereby detecting a small RNA molecule in a biological sample,” the application states.
 

 
Title: Genetic Inhibition by Double-Stranded RNA
 
Number: 20080081373
 
Filed: Oct. 1, 2007
 
Lead Inventor: Andrew Fire, Carnegie Institution
 
According to the patent application’s abstract, the invention comprises “a process … of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo.
 
“The RNA has a region with double-stranded structure,” the abstract notes. “Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The … invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods.”
 

 
Title: Methods of Using Combinations of siRNAs for Treating a Disease or Disorder and for Enhancing siRNA Efficacy in RNAi
 
Number: 20080081791
 
Filed: July 6, 2006
 
Lead Inventor: Weida Huang, Fudan University
 
The invention, the patent application’s abstract states, claims “methods for treating diseases or disorders and methods for enhancing siRNA efficacy in RNAi [that include] administering to a subject or a biological system one or more siRNAs capable of down-regulating the expression of one or more target genes, and one or more siRNAs capable of down-regulating the expression of one or more negative regulators of RNAi.”
 
According to the abstract, the invention also comprises “compositions including one or more siRNAs, or precursors thereof, capable of down-regulating the expression of one or more target genes and comprising one or more siRNAs, or precursors thereof, capable of down regulating the expression of one or more negative regulators of RNAi.”

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.